Falls: A marker of preclinical Alzheimer disease: A cohort study protocol

Rebecca M Bollinger
Audrey Keleman
Regina Thompson
Elizabeth Westerhaus
Anne M Fagan

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Authors
Rebecca M Bollinger, Audrey Keleman, Regina Thompson, Elizabeth Westerhaus, Anne M Fagan, Tammie Ls Benzinger, Suzanne E Schindler, Chengjie Xiong, David Balota, John C Morris, Beau M Ances, and Susan L Stark

Introduction Progression to symptomatic Alzheimer disease (AD) occurs slowly over a series of preclinical stages. Declining functional mobility may be an early indicator of loss of brain network integration and may lead to an increased risk of experiencing falls. It is unknown whether measures of functional mobility and falls are preclinical markers of AD. The purpose of this study is to examine (1) the relationship between falls and functional mobility with AD biomarkers to determine when falls occur within the temporal progression to symptomatic Alzheimer disease, and (2) the attentional compared with perceptual/motor systems that underlie falls and functional mobility changes seen with AD.

Methods and analysis This longitudinal cohort study will be conducted at the Knight Alzheimer Disease Research Center. Approximately 350 cognitively normal participants (with and without preclinical AD) will complete an in-home visit every year for 4 years. During each yearly assessment, functional mobility will be assessed using the Performance Oriented Mobility Assessment, Timed Up and Go, and Timed Up and Go dual task. Data regarding falls (including number and severity) will be collected monthly by self-report and confirmed through interviews. This study will leverage ongoing neuropsychological assessments and neuroimaging (including molecular imaging using positron emission tomography and MRI) performed by the Knight Alzheimer Disease Research Center. Relationships between falls and biomarkers of amyloid, tau and neurodegeneration will be evaluated.

Ethics and dissemination This study was approved by the Washington University in St Louis Institutional Review Board (reference number 201807135). Written informed consent will be obtained in the home prior to the collection of any study data. Results will be published in peer-reviewed publications and presented at national and international conferences.

Trial registration number NCT04949529; Pre-results.

INTRODUCTION

Alzheimer disease (AD) is a slowly progressive neurodegenerative disease that affects 60%–70% of the over 50 million people living with dementia worldwide.1 2 Progression to symptomatic AD occurs slowly through a series of preclinical stages marked by changes in molecular biomarkers that can be quantified by neuroimaging, cerebrospinal fluid (CSF) or plasma measures.3 4 Cognitively normal (CN) stage 0 individuals have no biomarker abnormalities. CN stage 1 individuals have only cerebral amyloidosis, CN stage 2 individuals have amyloidosis and neurodegeneration, and CN stage 3 individuals have evidence of amyloidosis, neurodegeneration and subtle cognitive changes.4 5 7 These preclinical stages of AD develop over decades and are considered clinically silent.5 However, emerging evidence suggests that impaired functional mobility (gait and balance) and subsequent falls8 may precede symptomatic cognitive impairment5 9. Declining functional mobility and increases in falls may be due to subtle changes in attention, executive, motor and sensory processing, and may be an early indicator of loss of integration between the central (CNS) and peripheral nervous systems (PNS).8 10 12

Falls are a leading cause of injury, long-term disability, premature institutionalisation and injury-related death in older individuals.13 14 Individuals with symptomatic AD have a 60%–80% increased risk of falling,
and those who fall are five times more likely to be institutionalised than similar individuals who do not fall.\textsuperscript{13,15} A knowledge gap exists as to whether functional mobility and falls could serve as preclinical markers of AD.\textsuperscript{16}

We previously demonstrated that falls occur at higher rates during the preclinical phase of AD, and the mechanisms that underlie the deterioration of cognitive function were associated with declines in gait and balance necessary for functional mobility.\textsuperscript{9} Functional connections in the brain, referred to as resting state functional connectivity (rs-fc), decrease in symptomatic AD.\textsuperscript{17} We observed a decrease in rs-fc for CN individuals with preclinical AD in the dorsal attention network (DAN), a set of brain regions involved in attentional control and planning.\textsuperscript{17} Functional connections both within the DAN and across other resting state networks (RSNs) may affect one’s functional mobility when attempting to navigate home and community environments. While self-reported performance is obtained from CN individuals (with and without preclinical AD), performance-based measures of everyday function are not recorded. Additional research is therefore needed to examine the relationship between functional mobility/falls and rs-fc, especially for CN individuals with preclinical AD.

For this longitudinal observational study, we will evaluate CN individuals (with and without preclinical AD) at baseline who are currently undergoing comprehensive clinical, neuropsychological and biomarker evaluations at the Knight Alzheimer Disease Research Center (Knight ADRC). Annually, we will conduct an in-home evaluation of fall risks and functional mobility and prospective ascertainment of falls. Comparisons of objective assessments of functional mobility will be performed with regard to measures of brain pathology (using in vivo markers of cerebral amyloidosis and neurodegeneration) to allow us to characterise when changes in falls and functional mobility occur during the preclinical stages of AD. We will also examine attentional compared with perceptual/motor systems that underlie falls and functional mobility in preclinical AD. Falls and functional mobility measures could serve as innovative, inexpensive screening tools to identify individuals at increased risk for progression to symptomatic AD. This may have important implications for the timing of interventions in secondary prevention trials in AD and for the development of more precise, effective treatments for individuals with AD.\textsuperscript{18}

**METHODS AND ANALYSIS**

**Participants**

In this longitudinal cohort study, community-dwelling older adults will be recruited from an existing cohort followed by the Knight ADRC. Inclusion criteria for this study are as follows: \(\geq 65\) years of age, CN (Clinical Dementia Rating (CDR))\textsuperscript{19} score of 0, indicating no dementia), and collection of biomarkers (CSF) and/or neuroimaging (positron emission tomography (PET) and/or MRI) within 2 years of study enrolment. Recruitment procedures for the Knight ADRC have been published previously.\textsuperscript{20}

**Recruitment**

Participants (N=350) will be recruited for in-home visits near the time of their annual clinical assessment at the Knight ADRC. Knight ADRC staff will approach participants who meet inclusion criteria about their interest regarding this study. If interested, potential participants will be referred to a study team member who will provide a detailed description of the study procedures and invite the individual to participate. Letters will also be sent to all eligible individuals to invite them to participate in this study. Written, informed consent will be obtained in the home prior to the collection of any study data. This study was approved by the Institutional Review Board at Washington University in St. Louis (reference number: 201807135).

**Study procedures**

All Knight ADRC participants in principle complete longitudinal clinical and neuropsychological assessment and biomarker studies of biofluids (blood, CSF) and neuroimaging (amyloid PET, structural and functional MRI; see grey boxes in figure 1). For this study, participants additionally will receive an annual in-home visit and will report falls prospectively for the duration of the study (see blue boxes in figure 1).

**Knight ADRC Clinical Assessment**\textsuperscript{21}

Knight ADRC participants complete an annual clinical assessment battery administered by an experienced clinician using a standardised protocol. During this visit, the CDR assesses the participant’s cognitive and functional performance: 0=CN, 0.5=very mild symptomatic AD, 1=mild symptomatic AD, 2=moderate symptomatic AD or 3=severe symptomatic AD.\textsuperscript{19} A neurological examination is performed for each participant. At enrolment, participants must have a CDR=0.

**Knight ADRC Psychometric/Neuropsychological Assessments**\textsuperscript{22}

Participants complete a standard 2-hour psychometric battery within 2 weeks of their annual clinical assessment by an experienced psychometrist and board-certified neurologist blinded to the participant’s preclinical AD status.\textsuperscript{22} A sensitive composite of attentional and executive control tests that is highly predictive of the transition from healthy ageing to symptomatic AD\textsuperscript{23–25} will be compared with functional mobility and fall measures.\textsuperscript{22}

**Biomarker acquisition/brain neuropathology assessments**\textsuperscript{26}

Participants also complete PET scans\textsuperscript{27} and MRI\textsuperscript{28} and undergo CSF and blood collection\textsuperscript{29,30} at the Knight ADRC every 3 years.

**PET imaging**

PET imaging will be conducted on a 3T Siemens Biograph mMR hybrid scanner using the radiotracer \textsuperscript{18}F Florbetapir (AV45) to detect in vivo presence of amyloid in
the brain. Quantitative image analysis will be performed using a standard amyloid imaging analysis protocol that uses FreeSurfer regions of interest (ROIs; Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, USA). Regional standardised uptake value ratios (SUVRs) will be obtained using the cerebellum as the reference region.

**Structural MRI**

High-resolution structural MRI scans will be acquired using a T1-weighted magnetisation-prepared rapid gradient echo sequence to analyse brain volumetrics. Images will be subsequently analysed using standard procedures developed at the Knight ADRC using FreeSurfer to delineate brain regions, including cortical and subcortical areas, typically affected by AD.

**Functional MRI/network dysfunction**

During the MRI scan, rs-fc scans will be obtained using a gradient spin-echo sequence. Participants will be instructed to fixate on a visual crosshair and not to fall asleep. Rs-fc pre-processing and post-processing will be performed using standardised, in-house methods. In preparation for correlation analysis, data will be spatially smoothed with a 6mm full-width at half maximum Gaussian blur. Then, temporal low-pass filtering (f<0.1 Hz) will be applied to the time series of each voxel. Finally, spurious variance will be removed using linear regression for (1) six parameters generated from head motion correction, (2) the whole brain signal and (3) signals from ventricular and cerebral white matter. An ROI-based analysis consisting of 298 seeds will be performed with a Pearson’s correlation coefficient computed between pairwise ROI time courses across all areas within RSNs. From these 298 seeds, correlation matrices will be generated for each participant. For the 13 RSNs, correlation coefficients across ROI pairs within a network will be averaged to form a composite score. Based on average matrices, both intra-network (diagonal) and inter-network (off diagonal) composite scores will be generated.

**CSF biomarkers**

CSF will be collected at approximately 08:00 following overnight fasting. About 20–30 mL of CSF is collected, centrifuged briefly at low speed, aliquoted into polypropylene tubes and then stored at ~80°C. Aβ40, Aβ42, total tau (tTau) and tau phosphorylated at 181 (pTau181) are measured by chemiluminescent enzyme immunoassay using a fully automated platform (LUMIPULSE G1200, Fujirebio) according to the manufacturer’s specifications. APOE genotype will be determined by genotyping rs7412 and rs429358 using Taqman genotyping technology as described previously.

**Preclinical AD staging**

Biomarker positivity will be defined by correlating biomarker values at baseline with the risk of developing AD symptoms over time. The derivation of the biomarker cut-offs will be independent of the data collected in this project. Of note, CSF markers of tauopathy (pTau181) and neurodegeneration and episodic memory are extremely highly correlated (r~0.96), so further stratification of stage by tauopathy would not be meaningful. Participants will be classified as follows: CN if measures of amyloid, neurodegeneration and episodic memory are normal; stage 1 if only measures of amyloid are abnormal by CSF Aβ42/Aβ40 or amyloid PET mean cortical SUVRs (which are highly concordant); stage 2 if only measures of amyloid and neurodegeneration (by CSF tTau) are abnormal; and stage 3 if measures of amyloid, neurodegeneration and episodic memory are abnormal.

**Annual in-home visit**

An occupational therapist (OT), blinded to participants’ preclinical AD status, will complete a 120–180 min in-home visit annually for 4 years. The OT will conduct assessments related to the PNS as well as in-home functional mobility and recognised fall covariates (tables 1 and 2). Although the annual visit is typically completed in one session, it will be completed over two sessions if needed due to participant fatigue and/or request. Participants

---

Figure 1  Research design overview. Measures of interest collected by the Knight Alzheimer Disease Research Center (Knight ADRC) will be available at no cost. In-home assessments will be collected annually, and falls will be monitored prospectively.
<table>
<thead>
<tr>
<th>Construct</th>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central nervous system</strong></td>
<td>Stroop colour naming task&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Colour naming of congruent (eg, red), neutral (eg, deep) or incongruent (eg, blue) word</td>
</tr>
<tr>
<td></td>
<td>Simon task&lt;sup&gt;52&lt;/sup&gt;</td>
<td>Naming direction of an arrow with a keypress that is spatially consistent or inconsistent with the location of the arrow including congruent and incongruent positioning</td>
</tr>
<tr>
<td></td>
<td>Attentional switching task&lt;sup&gt;53&lt;/sup&gt;</td>
<td>Switching every other trial between making odd-even decisions and consonant-vowel decisions on bivalent stimuli (eg, B14)</td>
</tr>
<tr>
<td><strong>Peripheral nervous system</strong></td>
<td>Centre of pressure path&lt;sup&gt;54&lt;/sup&gt;</td>
<td>Centre of pressure path will be measured using Balance Tracking System (BTrackS)</td>
</tr>
<tr>
<td></td>
<td>30-second chair stand test&lt;sup&gt;55&lt;/sup&gt;</td>
<td>A score below the norm will be considered indicative of decreased lower extremity strength and function</td>
</tr>
<tr>
<td></td>
<td>Handheld dynamometer&lt;sup&gt;56&lt;/sup&gt;</td>
<td>Minimal change in the peak torque value for lower extremity strength will be measured</td>
</tr>
<tr>
<td></td>
<td>Handheld dynamometer&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Pounds of force will be captured for grip strength</td>
</tr>
<tr>
<td></td>
<td>Early Treatment Diabetic Retinopathy Study (ETDRS) test&lt;sup&gt;58&lt;/sup&gt;</td>
<td>Visual acuity score; number of correct letters read</td>
</tr>
<tr>
<td></td>
<td>Pelli-Robson test&lt;sup&gt;59&lt;/sup&gt;</td>
<td>Contrast sensitivity; letter-by-letter</td>
</tr>
<tr>
<td><strong>Functional mobility</strong></td>
<td>Performance-Oriented Mobility Assessment (POMA)&lt;sup&gt;61&lt;/sup&gt;</td>
<td>A task-oriented assessment of 9 balance tasks and 7 items to assess gait</td>
</tr>
<tr>
<td></td>
<td>Timed Up and Go (TUG) test&lt;sup&gt;62&lt;/sup&gt;</td>
<td>Timed task of standing up, walking 3m, turning, walking back and sitting down</td>
</tr>
<tr>
<td></td>
<td>Timed Up and Go Cognitive (TUG&lt;sub&gt;cog&lt;/sub&gt;)&lt;sup&gt;63&lt;/sup&gt;</td>
<td>TUG test while reciting serial 3s with subtractions from various points</td>
</tr>
<tr>
<td></td>
<td>Timed Up and Go Manual (TUG&lt;sub&gt;man&lt;/sub&gt;)&lt;sup&gt;64&lt;/sup&gt;</td>
<td>TUG test while carrying a glass of water</td>
</tr>
<tr>
<td><strong>Additional assessments</strong></td>
<td>Short Michigan Alcoholism Screening Test—Geriatric Version (SMAST-G)&lt;sup&gt;65&lt;/sup&gt;</td>
<td>10-Item interview</td>
</tr>
<tr>
<td></td>
<td>Patient Health Questionnaire (PHQ-9)&lt;sup&gt;66&lt;/sup&gt;</td>
<td>10-Item questionnaire to assess frequency of symptoms; 0–27 points</td>
</tr>
<tr>
<td></td>
<td>Geriatric Depression Scale—Short Form (GDS-SF)&lt;sup&gt;67&lt;/sup&gt;</td>
<td>15-Item questionnaire; 0–15 points</td>
</tr>
<tr>
<td></td>
<td>Frequency and type&lt;sup&gt;68&lt;/sup&gt;</td>
<td>Short questionnaire of frequency and type (stress, urge or other)</td>
</tr>
<tr>
<td></td>
<td>Self-report&lt;sup&gt;69&lt;/sup&gt;</td>
<td>Pain scale from 12-item Short Form Survey</td>
</tr>
<tr>
<td></td>
<td>Medication review&lt;sup&gt;*&lt;/sup&gt;</td>
<td>Medications and dosages</td>
</tr>
<tr>
<td></td>
<td>Older Adults Resources and Services Activities of Daily Living (OARS ADL) scale&lt;sup&gt;70&lt;/sup&gt;</td>
<td>Ability to perform 14 activities; 0–2 scale, higher scores indicate greater independence</td>
</tr>
<tr>
<td></td>
<td>Performance Assessment of Self-Care Skills (PASS)&lt;sup&gt;71&lt;/sup&gt;</td>
<td>Evaluates independence, safety, and adequacy with shopping, chequebook balancing and medication management</td>
</tr>
<tr>
<td><strong>Falls behaviour</strong></td>
<td>Falls Behavioural Scale for Older People (FaB)&lt;sup&gt;72&lt;/sup&gt;</td>
<td>30-Item questionnaire; rated from 1 (least protective) to 4 (most protective) behaviours to prevent falls</td>
</tr>
<tr>
<td><strong>Self-efficacy</strong></td>
<td>Falls Efficacy Scale—International (FES-ISF)&lt;sup&gt;73&lt;/sup&gt;</td>
<td>7 daily activities; rated from 1 (not at all) to 4 (very concerned) about falling during specific activities</td>
</tr>
<tr>
<td><strong>Home hazards</strong></td>
<td>Westmead Home Safety Assessment (WeSHA)&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Rates 72 environmental home hazards as hazard/no hazard</td>
</tr>
<tr>
<td><strong>Olfaction</strong></td>
<td>University of Pennsylvania Smell Identification Test (UPSIT)&lt;sup&gt;75&lt;/sup&gt;</td>
<td>40-Item smell identification test; 0–40 points</td>
</tr>
<tr>
<td><strong>Hearing</strong></td>
<td>Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S)&lt;sup&gt;76&lt;/sup&gt;</td>
<td>10-Item questionnaire to screen for hearing impairment; 0–40 points</td>
</tr>
</tbody>
</table>

<sup>*</sup>Collected at the Knight ADRC.  
Knight ADRC, Knight Alzheimer Disease Research Center.
will receive a report with their results from the home visit and fall risk assessment based on established fall risk cut-off scores.38

Table 2 Fall covariate composite score variables

<table>
<thead>
<tr>
<th>Construct</th>
<th>Measure</th>
<th>Description</th>
<th>Fall risk cut-off38</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vision</td>
<td>Early Treatment Diabetic Retinopathy Study (ETDRS) test58, Pelli-Robson test59</td>
<td>Visual acuity score; number of correct letters read, Contrast sensitivity; letter-by-letter</td>
<td>≤12</td>
</tr>
<tr>
<td>Alcohol abuse</td>
<td>Short Michigan Alcoholism Screening Test—Geriatric Version (SMAST-G)65</td>
<td>10-Item interview</td>
<td>≥2</td>
</tr>
<tr>
<td>Depression</td>
<td>Geriatric Depression Scale—Short Form (GDS-SF)67*</td>
<td>15-Item questionnaire; 0-15 points</td>
<td>&gt;4</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>Frequency and type68</td>
<td>Short questionnaire of frequency and type (stress, urge or other)</td>
<td>≥weekly urge incontinence</td>
</tr>
<tr>
<td>Pain</td>
<td>Self-report69</td>
<td>Pain scale from 12-item Short Form Survey</td>
<td>≥moderate</td>
</tr>
<tr>
<td>Medication</td>
<td>Medication review*</td>
<td>Medications and dosages</td>
<td>≥4 medications</td>
</tr>
<tr>
<td>Functional capacity</td>
<td>Older Adults Resources and Services Activities of Daily Living (OARS ADL) scale70</td>
<td>Ability to perform 14 activities; 0-2 scale, higher scores indicate greater independence</td>
<td>&gt;4</td>
</tr>
<tr>
<td>Previous falls</td>
<td>Previous falls38</td>
<td>Total falls in the past 12 months, self-report</td>
<td>&gt;0</td>
</tr>
<tr>
<td>Home hazards</td>
<td>Westmead Home Safety Assessment (WeSHA)74</td>
<td>Rates 72 environmental home hazards as hazard/no hazard</td>
<td>≥4 hazards</td>
</tr>
<tr>
<td>Self-efficacy</td>
<td>Falls Efficacy Scale—International (FES-ISF)73</td>
<td>7 daily activities; rated from 1 (not at all) to 4 (very concerned) about falling during specific activities</td>
<td>&gt;10</td>
</tr>
</tbody>
</table>

*Collected at the Knight ADRC.

Monthly fall reporting
Participants will report falls prospectively via automated call or email every month for 4 years using the gold standard for fall reporting, including daily calendar journals, fall interviews and monetary compensation for reporting.37 Participants will also receive a standardised fall report form to record the time and location of a fall, nature of the fall environment, specific activity at the time of the fall and any somatic complaints that proceeded the fall.40 If a participant reports a fall, an interviewer blinded to preclinical AD status will call the participant to complete a fall interview to verify the fall, defined as an unintentional movement to the floor, ground or an object below knee level. The interviewer will then gather additional information about any subsequent injuries or medical treatment.9 41 42 The rate (number) and severity (calculated with a standardised algorithm from medical records and participant report) of falls will be generated.13 The falls severity score will be quantified using a previously published algorithm; no falls (0), 1 fall without serious injury (1), any fall with minor injury or more than 1 fall (2), and major injury requiring hospitalisation (3).14

Measures
An overview of the assessments collected at the Knight ADRC and annual in-home visits, including CNS and PNS measures, functional mobility, additional covariates of interest and fall covariates, for this study are listed in tables 1 and 2.

Statistical analysis plan
Data will be entered into Research Electronic Data Capture (REDCap),43 a secure, web-based application, and analysed using SAS, V.9.4 (SAS Institute). Differences in baseline characteristics across groups will be compared using appropriate statistics (χ² test, Student’s t-test or Mann-Whitney U test). Composites and cut-offs will be calculated as described in the Methods and analysis section (see table 2). Models for analysing AD biomarkers and cognition will include age, gender, fall risk composite score, APOE status (at least APOE ε4 allele), as well as possible interactions among study variables. Models will be implemented using PROC GLM or PROC MIXED/SAS.

Statistical analysis plan for the primary aim
We will examine the distributions of falls (number and severity) over a 1-year follow-up window and baseline functional mobility scores across the preclinical stages of AD (0, 1, 2 and 3),4 with appropriate transformations as needed. Falls severity scores across preclinical stages will be compared using analysis of covariance models.44 Similar analyses will be conducted to compare each of the functional mobility measures across the preclinical stages of AD. We will implement adequate approaches (e.g., Benjamini-Hochberg false discovery procedure)45 to control for the overall type I error rate due to multiple
outcome variables (number and severity of falls, functional mobility) tested in this aim.

We will also jointly model the longitudinal falls severity score and the time-to-symptom onset of AD (defined as the first time a participant receives a CDR >0) using general linear mixed effects models. 46 For modelling the risk of developing AD, we will use the semiparametric Cox proportional hazards model. To address the association between change in falls and the risk of developing symptomatic AD, we will implement joint models. 47 48

**Statistical analysis plan for the secondary aim**

We will test a hypothesised model of attentional compared with perceptual/motor systems underlying falls in preclinical AD using structural equation models (SEMs) on cross-sectional data. 49 The structural model will include the estimation of path coefficients among various latent constructs including brain neuropathology, network dysfunction, PNS abnormalities and falls. We will fit and compare various SEMs for their goodness-of-fit through standard statistics using multiple models.

**Sample size calculations**

**Primary aim**

To examine the relationship between falls, functional mobility and AD, we will enrol 350 older adults from the Knight ADRC. Based on the distribution of CN participants across clinical stages in the existing Knight ADRC database, the proposed sample size will provide at least 80% statistical power to detect an effect size as small as 0.225 SD on the falls severity score between two adjacent participant groups. From the Knight ADRC database, we fitted a survival curve from baseline to the time that a CDR >0 was first rendered. We found an estimated CDR progression rate of 7.2% per year for individuals with a mean age of 75 at baseline and an expected attrition of approximately 15%. We estimate that approximately 900 participants will be assessed annually throughout the study, and approximately 75 of these individuals will progress to CDR >0 after baseline. This will provide at least 80% statistical power to detect a onefold increase in the risk of developing symptomatic AD for individuals with an increased rate of falls over time compared with those with slow or no changes in falls over time. These power computations were based on a log rank test at the 5% significance level and assumed an annual rate of 4.7% of CDR progression for individuals with slow changes in disability over time.

**Secondary aim**

We also tested non-zero path coefficients that link the latent constructs of network dysfunction with attentional compared with perceptual/motor systems, and to impaired functional mobility and falls. The proposed sample provides at least 80% statistical power to detect each path coefficient.
development of more precise, effective treatments for individuals at risk for progression to symptomatic AD.18

**Twitter** Susan L Stark @PEPLaboratory

**Acknowledgements** We would like to thank the Knight Alzheimer Disease Research Center staff and all of our participants for making this study possible.

**Contributors** The study concept and design was conceived by SLS, BMA, CX, DB, and JCM. Patient safety protocols and IRB compliance will be managed by EW, RT and RMB. Recruitment and data collection will be conducted by RMB, RT and AK. Analysis will be performed by AMF; TLSB, SES and CX. The first draft of the protocol was prepared by BMA and SLS. All authors provided edits and approved the final version of the protocol.

**Funding** This work was supported by the National Institute on Aging (1 R01 AG057680-01A1), the Healthy Aging and Senile Dementia Program Project (P01 AG033991), the Knight Alzheimer Disease Research Center (P30 AG066444), Antecedent Biomarkers for AD: the Adult Children Study (P01 AG026276), the Paula C. and Rodger O. Riney Fund, and the Daniel J. Brennan MD Fund.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Rebecca M Bollinger http://orcid.org/0000-0002-1931-8372
Audrey Kelman http://orcid.org/0000-0003-1025-3100
Anne M Fagan http://orcid.org/0000-0002-5383-0214
Tammie LS Benzinger http://orcid.org/0000-0002-8114-0552
Suzanne E Schindler http://orcid.org/0000-0002-1680-1465
John C Morris http://orcid.org/0000-0001-9820-5618
Beau M Ancs http://orcid.org/0000-0003-3862-7397
Susan L Stark http://orcid.org/0000-0002-2816-7158

**REFERENCES**
